In this episode of Denatured, sponsored by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we discuss how biopharma has long invested in more data and visibility, yet many programs still face delays and scale-up surprises. The real challenge isn’t information overload—it’s building confidence in the decisions that steer scientific progress from development through commercialization.This episode is presented in partnership with Cytiva. HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestNicolas Pivet, VP & GM, Manufacturing & Digital Solutions, CytivaDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioSpace
Stability, speed and strategy: Inside Australia’s early‑stage edge
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
Why investors are taking another look at kidney disease
Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
Get summaries like this every morning.
Free AI-powered recaps of BioSpace and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.